Literature DB >> 7005347

Comparison of alloantisera and hybridoma antibody for purification of the H-2Db murine histocompatibility antigen and preliminary molecular characterization of this antigen.

W L Maloy, G Hämmerling, S G Nathenson, J E Coligan.   

Abstract

Previous studies on the determination of the complete amino acid sequence of H-2 molecules have relied on alloantisera to purify the H-2 molecules by immunoprecipitation. In this study, directed toward the determination of the complete amino acid sequence of the H-2Db molecule, it was found that all H-2.2 alloantisera examined had very low antibody titers when analyzed by immunoprecipitation and that most of these antisera reacted with not only the H-2Db heavy chain but also with a 75,000 dalton virus-associated glycoprotein (gp 75). The problems encountered with conventional alloantisera were surmounted by utilizing a monoclonal antibody from hybridoma B22-249R1 obtained as described by Hämmerling et al. (1979) and maintained in ascites form in (CBA x Balb/c) F1 mice. This antibody reacted with only 45,000 molecular weight material and had the added advantage of requiring only 0.1 ml of hybridoma ascites fluid to bind all of the H-2Db antigen from 3 x 10(8) EK-4 tumor cells. Biochemical examination of the purified H-2Db molecule showed that it possessed overall structural properties similar to other previously characterized H-2 molecules. An NH2-terminal amino acid sequence was determined for the H-2Db molecule for 28 residues and this sequence was compared to the complete NH2-terminal sequences of the H-2Kb and H-2Dd molecules, and the partial NH2-terminal sequence for the H-2Ld molecule; these comparisons indicated 82%, 75% and 100% homology respectively. In addition, these preliminary studies indicated that there was little or no beta-2-microglobulin (beta 2 mu) in the immunoprecipitates with the H2-2Db heavy chain. This lack of beta 2 mu in the immunoprecipitates was found to be true for alloantisera directed against private or public specificities, a xenoantiserum (sheep anti-H-2b), or hybridoma antibody used in the immunoprecipitation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7005347     DOI: 10.1016/0022-1759(80)90314-2

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

Review 1.  Class I genes and molecules: an update.

Authors:  A M Lew; E P Lillehoj; E P Cowan; W L Maloy; M R van Schravendijk; J E Coligan
Journal:  Immunology       Date:  1986-01       Impact factor: 7.397

2.  Antigenic determinants shared between HLA-A, -B, -C antigens and H-2 class I molecules modified by bovine beta-2 microglobulin.

Authors:  R Mierau; P J Robinson; A R Sanderson; E Genth; M Cramer
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

3.  A murine cell line defective in expression of several class I molecules.

Authors:  J M Martinko; S J Anderson; T Potter
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

4.  Primary structure of the H-2Db alloantigen. II. Additional amino acid sequence information, localization of a third site of glycosylation and evidence for K and D region specific sequences.

Authors:  W L Maloy; J E Coligan
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

5.  A comparison of the coding and 3'-noncoding DNA sequences of several murine transplantation antigens.

Authors:  A A Reyes; R B Wallace
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

6.  Differential expression of MHC class I antigens on the placenta of the rat. A mechanism for the survival of the fetal allograft.

Authors:  A Kanbour; H N Ho; D N Misra; T A MacPherson; H W Kunz; T J Gill
Journal:  J Exp Med       Date:  1987-12-01       Impact factor: 14.307

7.  Expression of H-2Db on the cell surface in the absence of detectable beta 2 microglobulin.

Authors:  T A Potter; C Boyer; A M Verhulst; P Golstein; T V Rajan
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.